Serum 3-Hydroxybutyrate in Patients with Psychogenic Somatoform Symptoms May Be a Predictor of the Effectiveness of Sertraline and Venlafaxine

References

• Katon WJ, Walker EA. Medically unexplained symptoms in primary care. J Clin Psychiatry. 1998;59:15–21.
   PubMed Web of Science ®Google Scholar
• Lepine J-P, Briley M. The epidemiology of pain in depression. Hum Psychopharmacol. 2004;19(S1):3–7. doi:10.1002/hup.618
   Web of Science ®Google Scholar
• Patetsos E, Horjales-Araujo E. Treating chronic pain with SSRIs: what do we know? Pain Res Manag. 2016;2016:2020915. doi:10.1155/2016/2020915
   PubMed Web of Science ®Google Scholar
• Grothe DR, Scheckner B, Albano D. Treatment of pain syndromes with venlafaxine. Pharmacotherapy. 2004;24(5):621–629. doi:10.1592/phco.24.6.621.34748
   PubMed Web of Science ®Google Scholar
• Huang X, Li C, Luo YL, Wang B, Ji JL. Efficacy of venlafaxine extended-release monotherapy for first-episode depression with painful physical symptoms. Neuroreport. 2013;24(7):364–369. doi:10.1097/WNR.0b013e3283601a3e
   PubMed Web of Science ®Google Scholar
• Kaddurah-Daouk R, Krishnan KR. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology. 2009;34(1):173–186. doi:10.1038/npp.2008.174
   PubMed Web of Science ®Google Scholar
• Setoyama D, Kato TA, Hashimoto R, et al. Plasma metabolites predict severity of depression and suicidal ideation in psychiatric patients-A multicenter pilot analysis. PLoS One. 2016;11(12):e0165267. doi:10.1371/journal.pone.0165267
   PubMed Web of Science ®Google Scholar
• Sada N, Lee S, Katsu T, Otsuki T, Inoue T. Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science. 2015;347(6228):1362–1367. doi:10.1126/science.aaa1299
   PubMed Web of Science ®Google Scholar
• Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21(3):263–269. doi:10.1038/nm.3804
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, et al. The mini-international neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:34–57.
   PubMed Web of Science ®Google Scholar
• Okun A, Stein RE, Bauman LJ, et al. Content validity of the psychiatric symptom index, CES-depression scale, and state-trait anxiety inventory from the perspective of DSM-IV. Psychol Rep. 1996;79(3):1059–1069. doi:10.2466/pr0.1996.79.3.1059
   PubMed Web of Science ®Google Scholar
• Spielberger CD, Gorsuch RL, Lushene RE. Manual for the State-Trait Anxiety. Palo Alto, CA: Consulting Psychologist Press; 1970.
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th. (DSM-V). VA: American Psychiatric Publishing; 2013
   Google Scholar
• 3-Hydroxybutyrate REAGENT KIT. KAINOS Co., Ltd. Tokyo, Japan. Available from: http://www.kainos.co.jp/jp/products/pdf/TKA5520.pdf. Accessed April 23, 2021. ( Japanese.)
   Google Scholar
• Drug information sheet of sertraline. (English) Pfizer Pharmaceuticals Inc. Available from: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1815. Accessed April 23, 2021.
   Google Scholar
• Drug information sheet of sertraline. (English) Pfizer Pharmaceuticals Inc. Available from: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=36222. Accessed April 23, 2021.
   Google Scholar
• Arora S, Henderson SO, Long T, et al. Diagnostic accuracy of point of care testing for diabetic ketoacidosis at emergency department triage: beta hydroxybutyrate versus the urine dipstick. Diabetes Care. 2011;34(4):852–854. doi:10.2337/dc10-1844
   PubMed Web of Science ®Google Scholar
• Noyes KJ, Crofton P, Bath LE, et al. Hydroxybutyrate near patient testing to evaluate a new end point for intravenous insulin therapy in the treatment of diabetic ketoacidosis in children. Pediatr Diabetes. 2007;8(3):150–156. doi:10.1111/j.1399-5448.2007.00240.x
   PubMed Web of Science ®Google Scholar
• Laffel LM, Wentzell K, Loughlin C, et al. Sick day management using blood 3-hydroxybutyrate (3-OHB) compared with urine ketone monitoring reduces hospital visits in young people with T1DM: a randomized clinical trial. Diabetes Med. 2006;23(3):278–284. doi:10.1111/j.1464-5491.2005.01771.x
   PubMed Web of Science ®Google Scholar
• Newman JC, Verdin E. Ketone bodies as signaling metabolites. Trends Endocrinol Metab. 2014;25(1):42–52. doi:10.1016/j.tem.2013.09.002
   PubMed Web of Science ®Google Scholar
• Cotter DG, Schugar RC, Crawford A. Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2013;304(8):1060–1076. doi:10.1152/ajpheart.00646.2012
   PubMed Web of Science ®Google Scholar
• Chen L, Miao Z, Xu X. Beta-hydroxybutyrate alleviates depressive behaviors in mice possibly by increasing the histone3-lysine9-beta-hydroxybutyrylation. Biochem Biophys Res Commun. 2017;490(2):117–122. doi:10.1016/j.bbrc.2017.05.184
   PubMed Web of Science ®Google Scholar
• Yamanashi T, Iwata M, Kamiya N, et al. Beta-hydroxybutyrate, an endogenic NLRP3 inflammasome inhibitor, attenuates stress-induced behavioral and inflammatory responses. Sci Rep. 2017;7(1):7677. doi:10.1038/s41598-017-08055-1
   PubMed Web of Science ®Google Scholar
• Kajitani N, Iwata M, Miura A, et al. Prefrontal cortex infusion of beta-hydroxybutyrate, an endogenous NLRP3 inflammasome inhibitor, produces antidepressant-like effects in a rodent model of depression. Neuropsychopharmacol Rep. 2020;40(2):157–165. doi:10.1002/npr2.12099
   PubMed Web of Science ®Google Scholar
• Manna V, Bolino F, Di Cicco L. Chronic tension-type headache, mood depression and serotonin: therapeutic effects of fluvoxamine and mianserine. Headache. 1994;34(1):44–49. doi:10.1111/j.1526-4610.1994.hed3401044.x
   PubMed Web of Science ®Google Scholar
• Keefe FJ, Shelby RA, Somers TJ, et al. Effects of copingskills training and sertraline in patients with non-cardiac chestpain: a randomized controlled study. Pain. 2011;152(4):730–741. doi:10.1016/j.pain.2010.08.040
   PubMed Web of Science ®Google Scholar
• Varia I, Logue E, O’Connor C, et al. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J. 2000;140(3):367–372. doi:10.1067/mhj.2000.108514
   PubMed Web of Science ®Google Scholar
• Aikens JE, Kroenke K, Nease DE, et al. Trajectories of improvement for six depression-related outcomes. Gen Hosp Psychiatry. 2008;30(1):26–31. doi:10.1016/j.genhosppsych.2007.10.003
   PubMed Web of Science ®Google Scholar
• Hieronymus F, Nilsson S, Eriksson E. A mega-analysis of fixeddose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. Transl Psychiatry. 2016;6(6):e834. doi:10.1038/tp.2016.104
   PubMed Web of Science ®Google Scholar
• Lisinski A, Hieronymus F, Eriksson E, et al. Low SSRI dosing in clinical practice-a register-based longitudinal study. Acta Psychiatr Scand. 2021;143(5):434–443. doi:10.1111/acps.13275
   PubMed Web of Science ®Google Scholar
• Redrobe JP, Bourin M, Colombel MC, et al. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology. 1998;138(1):1–8. doi:10.1007/s002130050638
   PubMed Web of Science ®Google Scholar
• Sakurai H, Uchida H, Kato M, et al. Pharmacological management of depression: Japanese expert consensus. J Affect Disord. 2020;266:626–632. doi:10.1016/j.jad.2020.01.149
   PubMed Web of Science ®Google Scholar
• Denis C, Fatséas M, Lavie E, et al. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev. 2006;19:CD005194.
   Google Scholar
• Lader M. Effectiveness of benzodiazepines: do they work or not? Expert Rev Neurother. 2008;8(8):1189–1191. doi:10.1586/14737175.8.8.1189
   PubMedGoogle Scholar
• Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs. 2009;23(1):19–34. doi:10.2165/0023210-200923010-00002
   PubMed Web of Science ®Google Scholar
• Penninkilampi R, Eslick GD. A systematic review and meta-analysis of the risk of dementia associated with benzodiazepine use, after controlling for protopathic bias. CNS Drugs. 2018;32(6):485–497. doi:10.1007/s40263-018-0535-3
   PubMed Web of Science ®Google Scholar
• Dodds TJ. Prescribed benzodiazepines and suicide risk: a review of the literature. Prim Care Companion CNS Disord. 2017;19(2). doi:10.4088/PCC.16r02037
   Google Scholar